Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:APVO NASDAQ:MITO NASDAQ:ZSAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.82-16.7%$0.90$0.57▼$3.15$27.01M0.3682,837 shs437,311 shsAPVOAptevo Therapeutics$1.60-2.1%$1.72$1.32▼$381.10$5.25M5.872.56 million shs1.26 million shsMITOStealth BioTherapeutics$0.32$0.32$0.16▼$1.03$23.54M1.46946,105 shsN/AZSANZosano Pharma$0.00$3.90$0.46▼$37.45$1K3.3425,375 shs5,685 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+4.05%-6.67%+24.21%-11.71%-63.02%APVOAptevo Therapeutics+1.87%-7.39%+10.88%-46.20%-99.96%MITOStealth BioTherapeutics0.00%0.00%0.00%0.00%0.00%ZSANZosano Pharma0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.82-16.7%$0.90$0.57▼$3.15$27.01M0.3682,837 shs437,311 shsAPVOAptevo Therapeutics$1.60-2.1%$1.72$1.32▼$381.10$5.25M5.872.56 million shs1.26 million shsMITOStealth BioTherapeutics$0.32$0.32$0.16▼$1.03$23.54M1.46946,105 shsN/AZSANZosano Pharma$0.00$3.90$0.46▼$37.45$1K3.3425,375 shs5,685 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+4.05%-6.67%+24.21%-11.71%-63.02%APVOAptevo Therapeutics+1.87%-7.39%+10.88%-46.20%-99.96%MITOStealth BioTherapeutics0.00%0.00%0.00%0.00%0.00%ZSANZosano Pharma0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 2.33Hold$3.30304.41% UpsideAPVOAptevo Therapeutics 2.33HoldN/AN/AMITOStealth BioTherapeutics 0.00N/AN/AN/AZSANZosano Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MITO, ZSAN, AKTX, and APVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025APVOAptevo TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)9/27/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025APVOAptevo TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)9/18/2025APVOAptevo TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/16/2025APVOAptevo TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/9/2025AKTXAkari TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.607/18/2025AKTXAkari TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/AAPVOAptevo Therapeutics$3.11M1.69N/AN/A$65.21 per share0.02MITOStealth BioTherapeutics$21.09M1.12N/AN/A($0.79) per share-0.41ZSANZosano Pharma$790K0.00N/AN/A$9.74 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-78.03%-31.62%11/18/2025 (Estimated)APVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-675.52%-175.68%11/6/2025 (Estimated)MITOStealth BioTherapeutics-$52.53M-$0.52N/AN/AN/AN/AN/A-142.81%N/AZSANZosano Pharma-$29.92M-$14.50N/A∞N/A-8,375.11%-177.06%-119.14%N/ALatest MITO, ZSAN, AKTX, and APVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025N/AAPVOAptevo Therapeutics-$2.09N/AN/AN/AN/AN/A8/11/2025Q2 2025APVOAptevo Therapeutics-$83.20-$8.40+$74.80-$8.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/AAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AMITOStealth BioTherapeuticsN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.190.19APVOAptevo TherapeuticsN/A2.272.27MITOStealth BioTherapeuticsN/A3.683.68ZSANZosano PharmaN/A1.611.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%APVOAptevo Therapeutics8.06%MITOStealth BioTherapeutics2.21%ZSANZosano PharmaN/AInsider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%APVOAptevo Therapeutics0.12%MITOStealth BioTherapeuticsN/AZSANZosano Pharma2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.62 million20.19 millionNot OptionableAPVOAptevo Therapeutics503.29 million3.28 millionNot OptionableMITOStealth BioTherapeutics2973.55 millionN/ANot OptionableZSANZosano Pharma404.90 million4.78 millionNot OptionableMITO, ZSAN, AKTX, and APVO HeadlinesRecent News About These CompaniesMicroneedles for Drug Delivery Patent Landscape Report and Forecast 2024-2032, Featuring Minnesota Mining and Manufacturing, BD and Co, Zosano Pharma, Raphas, Nano, and Pass TechnologiesMarch 7, 2025 | globenewswire.comNifty PharmaAugust 2, 2024 | economictimes.indiatimes.comThe seven steps to selling in pharmaJuly 31, 2024 | pharmaphorum.comPAktuelle Empfehlungen zur ZOSANOJuly 28, 2024 | finanznachrichten.deHOOK HOOKIPA Pharma Inc.April 12, 2024 | seekingalpha.comNachrichten - Weitere NachrichtenJanuary 9, 2024 | wallstreet-online.deWLISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy planDecember 6, 2023 | pbs.orgPDer Börsen-Tag: Diese US-Aktie stürzte nachbörslich abAugust 22, 2023 | n-tv.deNEast Bay Business NewsMay 18, 2023 | bizjournals.comMankind Pharma IPO opens on April 25, listing scheduled for May 9April 27, 2023 | moneycontrol.comAstellas PharmaApril 6, 2023 | forbes.comGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis FoundationFebruary 5, 2023 | finance.yahoo.comFTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by ordersJanuary 23, 2023 | washingtonexaminer.comWZosano Pharma Corporation (ZSANQ)November 5, 2022 | ca.finance.yahoo.comNow bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli LillyOctober 13, 2022 | endpts.comEBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma GiantsOctober 12, 2022 | msn.comBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of ClaimsAugust 28, 2022 | marketwatch.comEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionAugust 27, 2022 | bizjournals.comZosano Pharma Corp (ZSANQ)August 24, 2022 | investing.comEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1MJuly 26, 2022 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMITO, ZSAN, AKTX, and APVO Company DescriptionsAkari Therapeutics NASDAQ:AKTX$0.82 -0.16 (-16.73%) As of 03:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Aptevo Therapeutics NASDAQ:APVO$1.60 -0.04 (-2.15%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Stealth BioTherapeutics NASDAQ:MITOStealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.Zosano Pharma NASDAQ:ZSANZosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
